RxDoctor Payments DataLook up a doctor →

Francis Zidar, MD

Interventional Cardiology · Austin, TXNPI 1972580652

Payments from drug & device makers

$1,771,207in general payments, 2019–2025

Across 1,248 payments — averaging $1419.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$796K
  • Edwards Lifesciences$573K
  • Boston Scientific$327K
  • Medtronic$72K
  • Terumo Medical Corporation$1K
  • Ancora Heart, Inc.$624
  • plus $2K from 17 others
$1,200in research payments, 2019–2025

Across 1 payment — averaging $1200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Terumo Medical Corporation$1K

What the payments were for

  • Consulting fees$279,59265%
  • Speaking & faculty fees$104,42324%
  • Travel & lodging$30,7017%
  • Food & beverage$18,4174%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,771,207 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$535,216
Medicare patients
1,035
Services billed
3,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab121$125,265
EliquisApixaban40$44,587
Praluent PenAlirocumab42$33,172
VascepaIcosapent Ethyl31$13,055
Icosapent Ethyl30$6,386
Metoprolol Succinate395$5,568
Atorvastatin Calcium572$5,400
Rosuvastatin Calcium286$4,037
Ezetimibe174$3,820
Losartan Potassium161$2,267
Potassium Chloride76$1,580
Amlodipine Besylate176$1,479
Midodrine Hcl15$1,319
Valsartan29$926
Lisinopril98$889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$173$44,58740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →